出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年4月
Oligonucleotides Synthesis Market – Global Forecast To 2029
オリゴヌクレオチド合成市場 : 製品 [医薬品 (ASO、siRNA)、合成オリゴ (プライマー)、試薬、機器]、タイプ (カスタム、プレデザイン)、用途 [治療 (神経学、希少疾患)、研究 (PCR、シーケンス)、診断] – 2029年までの世界予測
Oligonucleotide Synthesis Market by Product (Drugs (ASO, siRNA), Synthesized Oligo (Primer), Reagents, Equipment), Type (Custom, Predesigned), Application (Therapeutic (Neurology, Rare), Research (PCR, Sequencing), Diagnostics) – Global Forecast to 2029
| ページ数 | 432 |
| 図表数 | 613 |
| 価格 | |
| シングルユーザライセンス | USD 4,950 |
| マルチユーザライセンス（5名） | USD 6,650 |
| コーポレートライセンス | USD 8,150 |
| エンタープライズサイトライセンス | USD 10,000 |
| 種別 | 英文調査報告書 |
[myphp file=”contact”] 出版社・価格・納期について
Report Overview
The oligonucleotide synthesis market is projected to reach USD 19.7 billion by 2029 from USD 8.8 billion in 2024, at a CAGR of 17.5% during the forecast period.
オリゴヌクレオチド合成市場は、予測期間中のCAGR 17.5%で、2024年の88億米ドルから2029年までに197億米ドルに達すると予測されています。
The synthesized oligonucleotide market is projected to reach USD 4.9 billion in 2029 from USD 2.2 billion in 2024, growing at a CAGR of 17.0% during the forecast period. The growth of this market is driven by several factors such as the increasing use of synthesized oligonucleotides such as primers and probes for various research and diagnostic applications. Technological advancements in the field of oligonucleotide synthesis further contribute to the growth of the market.
“The oligonucleotide synthesis market growth for synthesized oligonucleotides can be attributed to the growing research focused on thedevelopment of novel oligonucleotide-based drugs and their wide applications in diagnostic procedures.”
The oligonucleotide synthesis market, based on synthesized oligonucelotides (part of product segmentation), is further segmented into primer, probes, DNA Oligos, RNA Oligos, Other synthesized oigonucelotides. Synthesized oligonucelotides have a wide application in research for novel drug development and are mainly used in PCR and sequencing. Additionlly, diagnostic procedures used for detection of genetic disorders, companion diagnostics are also few of the major application areas for synthesized oligonucelotides.
“The primers segment will grow at the highest rate in the synthesized oligos market, by product.”
By Product, synthesized oligonucelotide maket is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos including BNA & LNA oligos. Primers are expected to grow at the highest rate during the forecasted period owing to the extensive use of primers in a wide range of applications such as PCR, sequencing, gene synthesis and cloning. Primers allow aplification of target gene sequences for gene expression studies, molecular diagnostics and genetic analysis.
“By therapeutic application, the neurological disease segment accounted for the largest share of the oligonucleotide synthesis market in 2023.”
The therapeutic application segment is segmented by disease type into neurological, rare and other diseases. In 2023, neurological disease segment accounted for the largest share of this segment as major companies are focusing on the development of oligo-based drugs for the treatment of neurological diseases such as DMD and SMA. Oligo based drugs that are used as therapies for these disorders have most FDA approvals.
“North American region is expected to register a highest CAGR in the oligonucleotide synthesis market.”
The market for oligonucleotide synthesis in North America is estimated to grow at the highest rate during the forecast period. Ongoing investments and funding provided by various government bodies, biotechnology and pharmaceutical companies to develop oligonucelotide based therapies for various rare and neurological disease, presence of strong venture capital ecosystem, growing awareness and early adoption of novel and alternate therapies in this region are few factors that support thr growth of this regional market. North America also has the established pharmceutical manufacturing infrastructure and the presence of the promnient players of the oligonucleotide synthesis market such as Danaher Corporation and Thermo Fisher among other which futher supports the leadership position of this region.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side – 30%
- By Designation: Managers- 45%, CXOs, and Director level – 30%, and Executives – 25%
- By Region: North America -35%, Europe – 25%, Asia-Pacific -15%, Latin America -10%, Middle East- 10%, Africa- 5%
List of Companies Profiled in the Report Offering Products For Research and Diagnostic Applications:
• Danaher Corporation (US)
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Eurofins Scientific (Luxembourg)
• LGC Limited (UK)
• Agilent Technologies, Inc. (US)
• Kaneka Corporation (Japan)
• Maravai Lifesciences holdings, Inc. (US)
• Azenta, Inc. (US)
• Twist Bioscience Corporation (US)
• Genscript Biotech Corporation (US)
List of Companies Profiled in the Report Offering Products For Therapeutic Applications:
• Biogen Inc. (US)
• Alnylam Pharmaceuticals, Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• Astrazeneca (UK)
• Astellas Pharma Inc. (Japan)
• Jazz Pharmaceuticals Plc (Ireland)
• Nippon Shinyaku, Co. Ltd. (Japan)
• Ionis Pharmaceuticals, Inc. (US)
• Novartis AG (Switzerland)
Note: Above list is inexhaustive
Research Coverage:
This report provides a detailed picture of the oligonucleotide synthesis market. It aims to estimate the market’s size and future growth potential across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, key market strategies, funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oligonucleotide synthesis market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (e.g., Increasing use of synthesized oligos in therapeutic and diagnostic applications, Technological advancements), restraints (e.g., complexities associated with oligonucleotide-based drugs), opportunities (e.g., increasing pharma R&D investments in emerging economies), and challenges (e.g., lack of standard regulations) are influencing the growth of the oligonucleotide synthesis market.
• Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the oligonucleotide synthesis market across varied regions.
• Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market.
• Pipeline Analysis: Comprehensive information about products under clinical trials.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), among others offering products for research & diagnostic applications and Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US) among others offering products for therapeutic applications.
Table of Contents
1 INTRODUCTION 63
1.1 STUDY OBJECTIVES 63
1.2 MARKET DEFINITION 63
1.3 INCLUSIONS & EXCLUSIONS 64
1.4 MARKET SCOPE 65
FIGURE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION 65
FIGURE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: REGIONAL SEGMENTATION 66
1.4.1 YEARS CONSIDERED 66
1.4.2 CURRENCY CONSIDERED 67
1.5 RESEARCH LIMITATIONS 67
1.6 STAKEHOLDERS 67
1.7 SUMMARY OF CHANGES 67
1.7.1 RECESSION IMPACT: OLIGONUCLEOTIDE SYNTHESIS MARKET 68
2 RESEARCH METHODOLOGY 69
2.1 RESEARCH DATA 69
FIGURE 3 RESEARCH DESIGN 69
2.1.1 SECONDARY DATA 70
2.1.2 PRIMARY DATA 71
FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 71
2.2 MARKET SIZE ESTIMATION 72
FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023 72
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1A (REVENUE SHARE ANALYSIS FOR RESEARCH & DIAGNOSTIC APPLICATIONS), 2023 73
FIGURE 7 MARKET SIZE ESTIMATION: APPROACH 1B (REVENUE SHARE ANALYSIS FOR THERAPEUTIC APPLICATIONS), 2023 73
FIGURE 8 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION (RESEARCH AND DIAGNOSTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2023 74
FIGURE 9 ILLUSTRATIVE EXAMPLE OF BIOGEN INC. (THERAPEUTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2023 74
FIGURE 10 MARKET VALIDATION FROM PRIMARY EXPERTS 76
2.2.1 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL 76
FIGURE 11 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 76
2.3 MARKET GROWTH FORECAST 77
FIGURE 12 CAGR PROJECTIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET, 2024–2029 78
FIGURE 13 CAGR PROJECTIONS: OLIGONUCLEOTIDE-BASED DRUGS MARKET (THERAPEUTIC APPLICATIONS), 2024–2029 78
FIGURE 14 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN OLIGONUCLEOTIDE SYNTHESIS MARKET 79
2.4 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION 79
2.5 MARKET BREAKDOWN & DATA TRIANGULATION 80
FIGURE 15 DATA TRIANGULATION METHODOLOGY 80
2.6 STUDY ASSUMPTIONS 81
2.7 RISK ANALYSIS 81
2.8 IMPACT OF RECESSION ON OLIGONUCLEOTIDE SYNTHESIS MARKET 81
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 81
TABLE 2 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION) 82
3 EXECUTIVE SUMMARY 83
FIGURE 16 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 83
FIGURE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 84
FIGURE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2024−2029 (USD MILLION) 84
FIGURE 19 GEOGRAPHICAL SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET 85
4 PREMIUM INSIGHTS 86
4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW 86
FIGURE 20 INCREASING USE OF SYNTHESIZED OLIGOS TO DRIVE MARKET GROWTH 86
4.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION AND COUNTRY (2023) 87
FIGURE 21 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023 87
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY PRODUCT, 2024 VS. 2029 87
FIGURE 22 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2029 87
4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2023 88
FIGURE 23 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 88
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 88
FIGURE 24 NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 88
5 MARKET OVERVIEW 89
5.1 INTRODUCTION 89
5.2 MARKET DYNAMICS 89
FIGURE 25 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 89
TABLE 3 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS 90
5.2.1 DRIVERS 90
5.2.1.1 Increasing use of synthesized oligos in therapeutic and diagnostic applications 90
TABLE 4 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016-2023) 91
5.2.1.2 Technological advancements 92
5.2.1.3 Growing government investments in life science research and synthetic biology 93
5.2.1.4 Growing focus on precision/personalized medicine 94
5.2.2 RESTRAINTS 94
5.2.2.1 Complexities associated with therapeutic oligonucleotides 94
5.2.3 OPPORTUNITIES 94
5.2.3.1 Increasing R&D investments by key players in emerging economies 94
5.2.4 CHALLENGES 95
5.2.4.1 Lack of standard regulations 95
5.2.4.2 Delivery of oligonucleotide drugs to specific targets 96
5.3 MARKET TRENDS 96
5.3.1 FOCUS ON DEVELOPING NEW DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS 96
5.3.2 FOCUS ON DEVELOPING NEW TECHNOLOGIES FOR SUSTAINABLE AND LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES 97
5.3.3 FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION 98
TABLE 5 LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 98
5.3.4 GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL AND RARE DISEASES 98
TABLE 6 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS 99
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 99
FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR OLIGONUCLEOTIDE MANUFACTURERS 99
5.5 SUPPLY CHAIN ANALYSIS 100
FIGURE 27 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES 101
5.6 VALUE CHAIN ANALYSIS 101
FIGURE 28 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 102
5.7 ECOSYSTEM ANALYSIS 103
FIGURE 29 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET 103
5.7.1 ROLE IN ECOSYSTEM 103
5.8 TECHNOLOGY ANALYSIS 104
5.8.1 KEY TECHNOLOGIES 104
5.8.1.1 Solid-phase synthesis 104
5.8.1.2 Liquid-phase synthesis 105
5.8.1.3 Enzymatic oligo synthesis 105
5.8.2 COMPLEMENTARY TECHNOLOGIES 105
5.8.2.1 Polymerase chain reaction (PCR) 105
5.8.2.2 Next-generation sequencing 106
5.8.3 ADJACENT TECHNOLOGIES 106
5.8.3.1 Clustered regularly interspaced short palindromic repeats (CRISPR) 106
5.9 PRICING ANALYSIS 106
TABLE 7 INDICATIVE PRICING OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS 106
TABLE 8 AVERAGE SELLING PRICE FOR MAJOR OLIGONUCLEOTIDE-BASED DRUGS 108
5.10 PATENT ANALYSIS 108
5.10.1 PATENTS FILED, BY DOCUMENT TYPE, 2012–2023 108
FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2012–DECEMBER 2023) 109
TABLE 9 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 109
5.11 PIPELINE ANALYSIS 111
FIGURE 31 NUMBER OF ONGOING CLINICAL TRIALS FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COMPANY 111
FIGURE 32 NUMBER OF ESTIMATED LAUNCHES, 2024–2028 112
TABLE 10 OLIGONUCLEOTIDE-BASED DRUGS IN CLINICAL PIPELINE 112
5.12 TRADE ANALYSIS 117
5.13 KEY CONFERENCES & EVENTS IN 2024–2025 117
TABLE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS 117
5.14 REGULATORY LANDSCAPE 118
5.14.1 REGULATORY ANALYSIS 118
5.14.2 REGULATORY BODIES 119
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 120
TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 120
TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 121
5.15 PORTER’S FIVE FORCES ANALYSIS 121
TABLE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 121
5.15.1 DEGREE OF COMPETITION 121
5.15.2 BARGAINING POWER OF SUPPLIERS 122
5.15.3 BARGAINING POWER OF BUYERS 122
5.15.4 THREAT OF SUBSTITUTES 122
5.15.5 THREAT OF NEW ENTRANTS 122
5.16 KEY STAKEHOLDERS & BUYING CRITERIA 123
5.16.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 123
5.16.2 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: HOSPITALS 123
5.17 KEY BUYING CRITERIA 124
5.17.1 BUYING CRITERIA OF END USERS FOR SYNTHESIZED OLIGONUCLEOTIDE PRODUCTS 124
5.17.2 BUYING CRITERIA FOR SYNTHESIZED OLIGONUCLEOTIDES, BY END USER 124
5.17.3 BUYING CRITERIA OF HOSPITALS FOR OLIGONUCLEOTIDE THERAPEUTIC PRODUCTS 125
5.17.4 BUYING CRITERIA FOR OLIGONUCLEOTIDE-BASED THERAPEUTIC PRODUCTS BY HOSPITALS 126
5.18 CASE STUDY ANALYSIS 127
5.18.1 CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT 127
5.18.2 CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING 127
5.18.3 CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA 127
5.19 INVESTMENT/FUNDING SCENARIO 128
6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT 129
6.1 INTRODUCTION 130
TABLE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 130
6.2 OLIGONUCLEOTIDE-BASED DRUGS 130
TABLE 19 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION) 131
TABLE 20 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 21 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 22 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 23 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 24 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 25 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 26 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT, 2022–2029 (NUMBER OF VIALS) 134
6.2.1 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE 134
TABLE 27 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 135
6.2.1.1 Antisense oligonucleotide-based drugs 135
6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth 135
TABLE 28 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS 136
TABLE 29 ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION) 136
TABLE 30 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 31 EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 32 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 33 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 34 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 35 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
6.2.1.2 siRNA oligonucleotide-based drugs 139
6.2.1.2.1 Large pipeline of products to favor market growth 139
TABLE 36 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS 140
TABLE 37 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION) 140
TABLE 38 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 39 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 40 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 41 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 42 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 43 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 142
6.2.1.3 Other oligonucleotide-based drugs 143
TABLE 44 APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS 143
TABLE 45 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022–2029 (USD MILLION) 144
TABLE 46 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 47 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 48 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 49 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 50 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 51 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 146
6.3 SYNTHESIZED OLIGONUCLEOTIDES 146
TABLE 52 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 147
TABLE 53 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 54 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 55 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 56 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 57 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 58 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 59 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 149
6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT 149
6.3.1.1 Primers 149
6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth 149
TABLE 60 OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2022–2029 (USD MILLION) 150
TABLE 61 NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 62 EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 63 ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 64 LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 65 MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 66 GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 152
6.3.1.2 Probes 153
6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth 153
TABLE 67 OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2022–2029 (USD MILLION) 154
TABLE 68 NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 69 EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 70 ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 71 LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 72 MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 73 GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 156
6.3.1.3 DNA oligonucleotides 156
6.3.1.3.1 Diverse usage of DNA oligos to support market growth 156
TABLE 74 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 157
TABLE 75 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 76 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 77 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 78 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 79 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 80 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 159
6.3.1.4 RNA oligonucleotides 159
6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth 159
TABLE 81 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 160
TABLE 82 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 83 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 84 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 85 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 86 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 87 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 162
6.3.1.5 Other synthesized oligonucleotides 162
TABLE 88 OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 163
TABLE 89 NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 90 EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 91 ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 92 LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 93 MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 94 GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 165
6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE 165
TABLE 95 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 165
6.3.2.1 Custom oligonucleotides 165
6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth 165
TABLE 96 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 166
TABLE 97 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 166
TABLE 98 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 167
TABLE 99 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 167
TABLE 100 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 101 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 102 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 168
6.3.2.2 Predesigned oligonucleotides 169
6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption 169
TABLE 103 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION) 169
TABLE 104 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 105 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 106 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 107 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 108 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 109 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
6.4 REAGENTS & CONSUMABLES 172
6.4.1 GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS 172
TABLE 110 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION) 172
TABLE 111 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 112 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 113 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 114 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 115 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 116 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
6.5 EQUIPMENT 175
6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET 175
TABLE 117 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION) 175
TABLE 118 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 119 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 120 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 121 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 122 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
TABLE 123 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 177
7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 178
7.1 INTRODUCTION 179
TABLE 124 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 179
7.2 THERAPEUTIC APPLICATIONS 179
TABLE 125 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 180
TABLE 126 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 127 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 128 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 129 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 130 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 131 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 182
7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE 183
TABLE 132 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 183
7.2.1.1 Neurological disorders 183
7.2.1.1.1 Growing research on use of oligonucleotide-based drugs for treatment of DMD and SMA to promote market growth 183
TABLE 133 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION) 184
TABLE 134 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 135 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 136 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 185
TABLE 137 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 138 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 139 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 186
7.2.1.2 Rare diseases 187
7.2.1.2.1 High specificity and efficacy of oligo-based drugs against rare diseases to support growth 187
TABLE 140 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2022–2029 (USD MILLION) 187
TABLE 141 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 142 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 143 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 144 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 145 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 146 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 189
7.2.1.3 Other diseases 190
TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION) 190
TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 152 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 153 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 192
7.3 RESEARCH APPLICATIONS 193
TABLE 154 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 155 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 193
TABLE 156 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 157 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 158 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 195
TABLE 159 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 195
TABLE 160 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 195
TABLE 161 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 196
7.3.1 PCR 196
7.3.1.1 Increasing use of PCR in molecular biology research to drive market growth 196
TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2022–2029 (USD MILLION) 197
TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 197
TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 197
TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 167 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 168 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022–2029 (USD MILLION) 199
7.3.2 SEQUENCING 199
7.3.2.1 Advancements in sequencing technologies and low cost of DNA sequencing to boost growth 199
TABLE 169 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2022–2029 (USD MILLION) 200
TABLE 170 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 171 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 201
TABLE 173 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 201
TABLE 174 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 201
TABLE 175 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 202
7.3.3 OTHER RESEARCH APPLICATIONS 202
TABLE 176 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 203
TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 178 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 179 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 204
TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 204
TABLE 181 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 204
TABLE 182 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 205
7.4 DIAGNOSTIC APPLICATIONS 205
7.4.1 INCREASING DEMAND FOR RELIABLE, SPECIFIC, AND FAST METHODS FOR DETECTION OF VARIOUS DISEASES TO SUPPORT GROWTH 205
TABLE 183 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 206
TABLE 184 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 185 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 186 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 207
TABLE 187 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 207
TABLE 188 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 207
TABLE 189 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 208
8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 209
8.1 INTRODUCTION 210
TABLE 190 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 210
8.2 HOSPITALS 210
8.2.1 INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET GROWTH 210
TABLE 191 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION) 211
TABLE 192 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 193 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 194 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 195 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 213
TABLE 196 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 213
TABLE 197 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 213
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 214
8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO DRIVE GROWTH 214
TABLE 198 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 215
TABLE 199 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 215
TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 215
TABLE 201 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 216
TABLE 202 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 216
TABLE 203 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 216
TABLE 204 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 217
8.4 DIAGNOSTIC LABORATORIES 217
8.4.1 GROWING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL GROWTH 217
TABLE 205 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 218
TABLE 206 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 218
TABLE 207 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 218
TABLE 208 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 210 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 219
TABLE 211 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 220
8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) 220
8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES PROVIDED BY CROS & CMOS TO FAVOR MARKET GROWTH 220
TABLE 212 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2022–2029 (USD MILLION) 221
TABLE 213 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION) 221
TABLE 214 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION) 222
TABLE 215 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION) 222
TABLE 216 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION) 223
TABLE 217 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION) 223
TABLE 218 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION) 223
8.6 ACADEMIC RESEARCH INSTITUTES 224
8.6.1 GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET GROWTH 224
TABLE 219 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION) 225
TABLE 220 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 225
TABLE 221 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 225
TABLE 222 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 226
TABLE 223 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 226
TABLE 224 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 226
TABLE 225 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 227
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION 228
9.1 INTRODUCTION 229
TABLE 226 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2022–2029 (USD MILLION) 229
9.2 NORTH AMERICA 230
FIGURE 33 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 230
TABLE 227 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 231
TABLE 228 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 231
TABLE 229 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 230 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 232
TABLE 231 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 232 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 233
TABLE 233 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 233
TABLE 234 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 235 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 234
9.2.1 US 234
9.2.1.1 Government initiatives and strategic developments by major players to drive market growth 234
TABLE 236 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 235
TABLE 237 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 238 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 236
TABLE 239 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 240 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 236
TABLE 241 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 237
TABLE 242 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 243 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 237
9.2.2 CANADA 238
9.2.2.1 Strong research infrastructure and availability of funding to support market growth 238
TABLE 244 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 238
TABLE 245 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 246 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 239
TABLE 247 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 248 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 240
TABLE 249 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 240
TABLE 250 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 240
TABLE 251 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 241
9.2.3 NORTH AMERICA: RECESSION IMPACT 241
9.3 EUROPE 242
FIGURE 34 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 242
TABLE 252 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 243
TABLE 253 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 243
TABLE 254 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 244
TABLE 255 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 244
TABLE 256 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 244
TABLE 257 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 245
TABLE 258 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 245
TABLE 259 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 246
9.3.1 GERMANY 246
9.3.1.1 Government and private funding towards health research to support market growth 246
TABLE 261 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 247
TABLE 262 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 263 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 248
TABLE 264 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 265 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 248
TABLE 266 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 249
TABLE 267 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 249
TABLE 268 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 249
9.3.2 UK 250
9.3.2.1 Strategic collaborations and partnerships between key market players to favor market growth 250
TABLE 269 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 251
TABLE 270 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 251
TABLE 271 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 251
TABLE 272 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 273 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 252
TABLE 274 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 252
TABLE 275 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 253
TABLE 276 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 253
9.3.3 FRANCE 253
9.3.3.1 Government initiatives to strengthen R&D activities and growing awareness to propel market growth 253
TABLE 277 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 254
TABLE 278 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 254
TABLE 279 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 255
TABLE 280 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 281 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 255
TABLE 282 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 256
TABLE 283 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 256
TABLE 284 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 256
9.3.4 ITALY 257
9.3.4.1 Increasing research spending and presence of major pharmaceutical and biotechnology companies to drive market 257
TABLE 285 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 257
TABLE 286 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 258
TABLE 287 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 258
TABLE 288 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 258
TABLE 289 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 259
TABLE 290 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 259
TABLE 291 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 259
TABLE 292 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 260
9.3.5 SPAIN 260
9.3.5.1 Research and expansion initiatives to propel market growth 260
TABLE 293 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 261
TABLE 294 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 295 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 261
TABLE 296 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 262
TABLE 297 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 262
TABLE 298 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 262
TABLE 299 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 263
TABLE 300 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 263
9.3.6 REST OF EUROPE 263
TABLE 301 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 264
TABLE 302 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 264
TABLE 303 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 265
TABLE 304 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 265
TABLE 305 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 265
TABLE 306 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 266
TABLE 307 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 266
TABLE 308 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 266
9.3.7 EUROPE: RECESSION IMPACT 267
9.4 ASIA PACIFIC 267
TABLE 309 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 267
TABLE 310 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 268
TABLE 311 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 268
TABLE 312 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 269
TABLE 313 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 269
TABLE 314 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 269
TABLE 315 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 270
TABLE 316 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 270
TABLE 317 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 270
9.4.1 CHINA 271
9.4.1.1 Expansion of major biotechnology and pharmaceutical companies in China to boost market 271
TABLE 318 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 272
TABLE 319 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 320 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 273
TABLE 321 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 322 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 273
TABLE 323 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 274
TABLE 324 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 274
TABLE 325 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 274
9.4.2 JAPAN 275
9.4.2.1 Growing research initiatives and strategic developments to drive market growth in Japan 275
TABLE 326 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 275
TABLE 327 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 276
TABLE 328 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 276
TABLE 329 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 276
TABLE 330 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 277
TABLE 331 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 277
TABLE 332 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 277
TABLE 333 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 278
9.4.3 INDIA 278
9.4.3.1 Strong initiatives to develop bioclusters and increasing adoption of genomic technologies to aid market growth 278
TABLE 334 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 279
TABLE 335 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 279
TABLE 336 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 279
TABLE 337 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 280
TABLE 338 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 280
TABLE 339 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 280
TABLE 340 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 281
TABLE 341 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 281
9.4.4 AUSTRALIA 281
9.4.4.1 Increasing government initiatives and research funding to support market growth 281
TABLE 342 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 282
TABLE 343 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 282
TABLE 344 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 283
TABLE 345 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 283
TABLE 346 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 283
TABLE 347 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 284
TABLE 348 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 284
TABLE 349 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 284
9.4.5 SOUTH KOREA 285
9.4.5.1 Growing research activities and strategic expansions in field of oligonucleotide synthesis to propel market growth 285
TABLE 350 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 285
TABLE 351 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 286
TABLE 352 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 286
TABLE 353 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 286
TABLE 354 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 287
TABLE 355 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 287
TABLE 356 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 287
TABLE 357 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 288
9.4.6 REST OF ASIA PACIFIC 288
TABLE 358 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 289
TABLE 359 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 289
TABLE 360 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 290
TABLE 361 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 290
TABLE 362 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 290
TABLE 363 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 291
TABLE 364 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 291
TABLE 365 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 291
9.4.7 ASIA PACIFIC: RECESSION IMPACT 292
9.5 LATIN AMERICA 292
TABLE 366 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 292
TABLE 367 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 293
TABLE 368 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 293
TABLE 369 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 294
TABLE 370 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 294
TABLE 371 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 294
TABLE 372 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 295
TABLE 373 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 295
TABLE 374 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 295
9.5.1 BRAZIL 296
9.5.1.1 Availability of major oligo-based therapies to support market growth 296
TABLE 375 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 296
TABLE 376 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 296
TABLE 377 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 297
TABLE 378 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 297
TABLE 379 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 297
TABLE 380 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 298
TABLE 381 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 298
TABLE 382 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 298
9.5.2 MEXICO 299
9.5.2.1 Growing adoption of NGS technology and increasing research and awareness towards oligonucleotide-based therapies to support growth 299
TABLE 383 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 299
TABLE 384 MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 300
TABLE 385 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 300
TABLE 386 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 300
TABLE 387 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 301
TABLE 388 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 301
TABLE 389 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 301
TABLE 390 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 302
9.5.3 ARGENTINA 302
9.5.3.1 Increase in research collaborations and government support to boost market growth 302
TABLE 391 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 303
TABLE 392 ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 303
TABLE 393 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 304
TABLE 394 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 304
TABLE 395 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 304
TABLE 396 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 305
TABLE 397 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 305
TABLE 398 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 305
9.5.4 REST OF LATIN AMERICA 306
TABLE 399 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 306
TABLE 400 REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 306
TABLE 401 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 307
TABLE 402 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 307
TABLE 403 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 307
TABLE 404 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 308
TABLE 405 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 308
TABLE 406 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 308
9.5.5 LATIN AMERICA: RECESSION IMPACT 309
9.6 MIDDLE EAST 309
TABLE 407 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 309
TABLE 408 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 310
TABLE 409 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 310
TABLE 410 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 311
TABLE 411 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 311
TABLE 412 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 311
TABLE 413 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 312
TABLE 414 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 312
TABLE 415 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 312
9.6.1 GCC COUNTRIES 313
TABLE 416 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 313
TABLE 417 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 313
TABLE 418 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 314
TABLE 419 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 314
TABLE 420 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 314
TABLE 421 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 315
TABLE 422 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 315
TABLE 423 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 315
TABLE 424 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 316
9.6.1.1 Saudi Arabia (KSA) 316
9.6.1.1.1 Increasing focus on research and government support to propel market growth 316
TABLE 425 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 317
TABLE 426 SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 317
TABLE 427 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 318
TABLE 428 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 318
TABLE 429 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 318
TABLE 430 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 319
TABLE 431 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 319
TABLE 432 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 319
9.6.1.2 United Arab Emirates (UAE) 320
9.6.1.2.1 Government-driven initiatives and investments to boost market growth 320
TABLE 433 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 320
TABLE 434 UAE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 321
TABLE 435 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 321
TABLE 436 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 321
TABLE 437 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 322
TABLE 438 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 322
TABLE 439 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 322
TABLE 440 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 323
9.6.1.3 Rest of GCC Countries 323
TABLE 441 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 323
TABLE 442 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 324
TABLE 443 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 324
TABLE 444 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 324
TABLE 445 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 325
TABLE 446 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 325
TABLE 447 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 325
TABLE 448 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 326
9.6.2 REST OF MIDDLE EAST 326
TABLE 449 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 326
TABLE 450 REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 327
TABLE 451 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 327
TABLE 452 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 327
TABLE 453 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 328
TABLE 454 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 328
TABLE 455 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 328
TABLE 456 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 329
9.6.3 MIDDLE EAST: RECESSION IMPACT 329
9.7 AFRICA 329
9.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH 329
TABLE 457 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 330
TABLE 458 AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022–2029 (USD MILLION) 330
TABLE 459 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 331
TABLE 460 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022–2029 (USD MILLION) 331
TABLE 461 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 331
TABLE 462 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022–2029 (USD MILLION) 332
TABLE 463 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 332
TABLE 464 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022–2029 (USD MILLION) 332
9.7.2 AFRICA: RECESSION IMPACT 333
10 COMPETITIVE LANDSCAPE 334
10.1 INTRODUCTION 334
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 334
10.2.1 KEY PLAYERS STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2021–2024 335
10.2.2 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS), 2021–2024 336
10.3 REVENUE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS) 337
FIGURE 35 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2021–2023 337
10.4 MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS) 338
FIGURE 36 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS), BY KEY PLAYER, 2023 338
TABLE 465 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): DEGREE OF COMPETITION 339
10.5 REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS) 339
FIGURE 37 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2021–2023 340
FIGURE 38 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS), BY KEY PLAYER, 2023 341
TABLE 466 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): DEGREE OF COMPETITION 341
10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2023 342
10.6.1 STARS 342
10.6.2 EMERGING LEADERS 343
10.6.3 PERVASIVE PLAYERS 343
10.6.4 PARTICIPANTS 343
FIGURE 39 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2023 344
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2023 344
10.7.1 STARS 345
10.7.2 EMERGING LEADERS 345
10.7.3 PERVASIVE PLAYERS 345
10.7.4 PARTICIPANTS 345
FIGURE 40 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2023 346
10.7.5 COMPANY FOOTPRINT ANALYSIS 347
FIGURE 41 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): COMPANY FOOTPRINT 347
TABLE 467 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): PRODUCT FOOTPRINT 347
TABLE 468 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): APPLICATION FOOTPRINT 348
TABLE 469 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): REGIONAL FOOTPRINT 349
FIGURE 42 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): COMPANY FOOTPRINT 350
TABLE 470 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): REGIONAL FOOTPRINT 350
TABLE 471 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): PRODUCT FOOTPRINT 351
TABLE 472 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): APPLICATION FOOTPRINT 351
10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 352
10.8.1 PROGRESSIVE COMPANIES 352
10.8.2 RESPONSIVE COMPANIES 352
10.8.3 DYNAMIC COMPANIES 352
10.8.4 STARTING BLOCKS 352
FIGURE 43 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2023 353
10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 354
TABLE 473 DETAILED LIST OF KEY STARTUPS/SMES 354
TABLE 474 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 355
10.9 COMPETITIVE SCENARIO 355
10.9.1 PRODUCT APPROVALS 355
TABLE 475 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT APPROVALS, JANUARY 2021–FEBRUARY 2024 355
TABLE 476 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS, JANUARY 2021-FEBRUARY 2024 356
TABLE 477 OLIGONUCLEOTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2021-FEBRUARY 2024 357
10.10 VALUATION AND FINANCIAL METRICS OF OLIGONUCLEOTIDE SYNTHESIS MARKET VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS) 359
FIGURE 44 EV/EBITDA OF KEY VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS) 359
FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS) 359
10.11 VALUATION AND FINANCIAL METRICS OF OLIGONUCLEOTIDE SYNTHESIS MARKET VENDORS (THERAPEUTIC APPLICATIONS) 360
FIGURE 46 EV/EBITDA OF KEY VENDORS (THERAPEUTIC APPLICATIONS) 360
FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (THERAPEUTIC APPLICATIONS) 360
10.12 BRAND/PRODUCT COMPARATIVE ANALYSIS 361
10.12.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH AND DIAGNOSTIC APPLICATIONS) 361
10.12.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS) 362
11 COMPANY PROFILES 363
(Business overview, Products offered, Recent Developments, MNM view)*
11.1 KEY PLAYERS 363
11.1.1 DANAHER CORPORATION 363
TABLE 478 DANAHER CORPORATION: COMPANY OVERVIEW 363
FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2023) 364
TABLE 479 DANAHER CORPORATION: PRODUCTS OFFERED 364
TABLE 480 DANAHER CORPORATION: DEALS 368
TABLE 481 DANAHER CORPORATION: EXPANSIONS 368
TABLE 482 DANAHER CORPORATION: OTHER DEVELOPMENTS 369
11.1.2 THERMO FISHER SCIENTIFIC INC. 370
TABLE 483 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 370
FIGURE 49 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 371
TABLE 484 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 371
TABLE 485 THERMO FISHER SCIENTIFIC INC.: DEALS 374
11.1.3 MERCK KGAA 375
TABLE 486 MERCK KGAA: COMPANY OVERVIEW 375
FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT (2023) 376
TABLE 487 MERCK KGAA: PRODUCTS OFFERED 376
TABLE 488 MERCK KGAA: EXPANSIONS 379
11.1.4 LGC LIMITED 381
TABLE 489 LGC LIMITED: COMPANY OVERVIEW 381
FIGURE 51 LGC LIMITED: COMPANY SNAPSHOT (2023) 382
TABLE 490 LGC LIMITED: PRODUCTS OFFERED 382
TABLE 491 LGC LIMITED: DEALS 384
TABLE 492 LGC LIMITED: EXPANSIONS 385
11.1.5 EUROFINS SCIENTIFIC 386
TABLE 493 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 386
FIGURE 52 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023) 387
TABLE 494 EUROFINS SCIENTIFIC: PRODUCTS OFFERED 387
TABLE 495 EUROFINS SCIENTIFIC: DEALS 389
11.1.6 AGILENT TECHNOLOGIES, INC. 390
TABLE 496 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 390
FIGURE 53 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 391
TABLE 497 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 391
TABLE 498 AGILENT TECHNOLOGIES, INC.: EXPANSIONS 392
11.1.7 KANEKA CORPORATION 393
TABLE 499 KANEKA CORPORATION: COMPANY OVERVIEW 393
FIGURE 54 KANEKA CORPORATION: COMPANY SNAPSHOT (2023) 394
TABLE 500 KANEKA CORPORATION: PRODUCTS OFFERED 394
TABLE 501 KANEKA CORPORATION: EXPANSIONS 396
11.1.8 MARAVAI LIFESCIENCES HOLDINGS, INC. 397
TABLE 502 MARAVAI LIFESCIENCES HOLDINGS, INC.: COMPANY OVERVIEW 397
FIGURE 55 MARAVAI LIFESCIENCES HOLDINGS, INC.: COMPANY SNAPSHOT (2023) 398
TABLE 503 MARAVAI LIFESCIENCES HOLDINGS, INC.: PRODUCTS OFFERED 398
TABLE 504 MARAVAI LIFESCIENCES HOLDINGS, INC.: DEALS 401
11.1.9 AZENTA, INC. 402
TABLE 505 AZENTA, INC.: COMPANY OVERVIEW 402
FIGURE 56 AZENTA, INC.: COMPANY SNAPSHOT (2023) 403
TABLE 506 AZENTA, INC.: PRODUCTS OFFERED 403
11.1.10 TWIST BIOSCIENCE CORPORATION 405
TABLE 507 TWIST BIOSCIENCE CORPORATION: COMPANY OVERVIEW 405
FIGURE 57 TWIST BIOSCIENCE CORPORATION: COMPANY SNAPSHOT (2023) 406
TABLE 508 TWIST BIOSCIENCE CORPORATION: PRODUCTS OFFERED 406
TABLE 509 TWIST BIOSCIENCE CORPORATION: DEALS 407
11.1.11 GENSCRIPT BIOTECH CORPORATION 408
TABLE 510 GENSCRIPT BIOTECH CORPORATION: COMPANY OVERVIEW 408
FIGURE 58 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2022) 409
TABLE 511 GENSCRIPT BIOTECH CORPORATION: PRODUCTS OFFERED 409
TABLE 512 GENSCRIPT BIOTECH CORPORATION: EXPANSIONS 411
11.2 KEY PLAYERS (THERAPEUTIC PRODUCTS) 412
11.2.1 BIOGEN INC. 412
TABLE 513 BIOGEN INC.: COMPANY OVERVIEW 412
FIGURE 59 BIOGEN INC.: COMPANY SNAPSHOT (2023) 413
TABLE 514 BIOGEN INC.: PRODUCTS OFFERED 413
TABLE 515 BIOGEN INC.: PRODUCT APPROVALS 414
TABLE 516 BIOGEN INC.: DEALS 414
TABLE 517 BIOGEN INC.: EXPANSIONS 415
11.2.2 ALNYLAM PHARMACEUTICALS, INC. 416
TABLE 518 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 416
FIGURE 60 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023) 417
TABLE 519 ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED 417
TABLE 520 ALNYLAM PHARMACEUTICALS INC.: PRODUCT APPROVALS 418
TABLE 521 ALNYLAM PHARMACEUTICALS INC.: DEALS 418
11.2.3 SAREPTA THERAPEUTICS, INC. 420
TABLE 522 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 420
FIGURE 61 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2023) 420
TABLE 523 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED 421
TABLE 524 SAREPTA THERAPEUTICS: PRODUCT APPROVALS 421
TABLE 525 SAREPTA THERAPEUTICS: DEALS 421
TABLE 526 SAREPTA THERAPEUTICS: EXPANSIONS 422
11.2.4 ASTRAZENECA 423
TABLE 527 ASTRAZENECA: COMPANY OVERVIEW 423
FIGURE 62 ASTRAZENECA: COMPANY SNAPSHOT (2023) 424
TABLE 528 ASTRAZENECA: PRODUCTS OFFERED 424
TABLE 529 ASTRAZENECA: DEALS 424
TABLE 530 ASTRAZENECA: PRODUCT APPROVALS 425
11.2.5 ASTELLAS PHARMA INC. 426
TABLE 531 ASTELLAS PHARMA INC.: COMPANY OVERVIEW 426
FIGURE 63 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2022) 426
TABLE 532 ASTELLAS PHARMA INC.: PRODUCTS OFFERED 427
TABLE 533 ASTELLAS PHARMA INC.: DEALS 427
TABLE 534 ASTELLAS PHARMA INC.: PRODUCT APPROVALS 427
11.2.6 JAZZ PHARMACEUTICALS PLC 428
TABLE 535 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW 428
FIGURE 64 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2023) 429
TABLE 536 JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED 429
11.2.7 NIPPON SHINYAKU, CO. LTD. (NS PHARMA, INC.) 430
TABLE 537 NIPPON SHINYAKU, CO. LTD.: COMPANY OVERVIEW 430
FIGURE 65 NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2022) 430
TABLE 538 NIPPON SHINYAKU, CO. LTD.: PRODUCTS OFFERED 431
11.2.8 IONIS PHARMACEUTICALS, INC. 432
TABLE 539 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 432
FIGURE 66 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023) 432
TABLE 540 IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED 433
TABLE 541 IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS 433
TABLE 542 IONIS PHARMACEUTICALS, INC.: DEALS 434
11.2.9 NOVARTIS AG 435
TABLE 543 NOVARTIS AG: COMPANY OVERVIEW 435
FIGURE 67 NOVARTIS AG: COMPANY SNAPSHOT (2023) 436
TABLE 544 NOVARTIS AG: PRODUCTS OFFERED 436
TABLE 545 NOVARTIS AG: PRODUCT APPROVALS 437
TABLE 546 NOVARTIS AG: DEALS 437
11.3 OTHER PLAYERS 438
11.3.1 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S) 438
11.3.2 BIOLEGIO BV 439
11.3.3 BIOLYTIC LAB PERFORMANCE, INC. 440
11.3.4 BIOCOMMA LIMITED 441
11.3.5 REVVITY, INC. (THROUGH SUBSIDIARY HORIZON DISCOVERY LTD.) 442
11.3.6 BIO-SYNTHESIS, INC. 443
11.3.7 CREATIVE BIOGENE 444
11.3.8 REPROCELL, INC. (THROUGH SUBSIDIARY BIOSERVE) 446
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX 447
12.1 DISCUSSION GUIDE 447
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 451
12.3 RELATED REPORTS 453
12.4 AUTHOR DETAILS 454